Christopher Bonzon, MD
Physical Medicine & Rehabilitation · Redwood City, CANPI 1215197199
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Assertio Therapeutics, Inc. at 39.4% of the total. Reporting peaked in 2019 at $88 and has fallen 72.7% since, to $24 in 2025. That places this record below the midpoint for physical medicine & rehabilitation clinicians in CA, where the typical reported total is $142.
Across 8 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Assertio Therapeutics, Inc.$57
- Amgen$30
- Abbott$24
- Boston Scientific$18
- Ferring Pharmaceuticals Inc.$16
What the payments were for
- Food & beverage$145100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Assertio Therapeutics, Inc. | 3 | $57 |
| Amgen | 2 | $30 |
| Abbott | 1 | $24 |
| Boston Scientific | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
How this compares
$145 in reported general payments places this provider in the 50th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 18 | $2,338 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $1,941 |
| Gabapentin | 131 | $1,685 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 45 | $1,033 |
| Oxycodone Hcl | 26 | $656 |
| Pregabalin | 19 | $440 |
| Cyclobenzaprine Hcl | 29 | $371 |
| Prednisone | 72 | $318 |
| Tramadol Hcl | 52 | $307 |
| Lorazepam | 37 | $220 |
| Meloxicam | 29 | $84 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Redwood City
- Ziyad AyyoubParamount$322K
- Pratik GandhiAnaheim$122K
- Mary OatesSanta Maria$115K
- Kevin BarretteSan Francisco$84K
- Steven SampsonLos Angeles$63K
- Jeffrey ChenSan Diego$59K
- Nanette JoyceSacramento$56K
- Amir RahnavardMonterey$49K
- Kyle RyanSan Diego$39K
- Kyle YangLos Angeles$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.